Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Brain Volume Changes Over 1 Year in Ozanimod-treated Patients with Early-relapsing Multiple Sclerosis: An Interim Analysis of the ENLIGHTEN Study
Multiple Sclerosis
P11 - Poster Session 11 (5:30 PM-6:30 PM)
6-017
Whole brain volume (WBV) declines with normal aging (−0.28%/y). Patients with multiple sclerosis (MS) often have accelerated WBV loss.
To report brain volume changes over 1 year in ENLIGHTEN participants.
ENLIGHTEN (NCT04140305) is an open-label study of ozanimod 0.92 mg in patients with early relapsing MS. Percent change in brain volumes over 1 year are analyzed using SIENA (for WBV), FreeSurfer (for thalamic volume [TV] and medulla oblongata volume [MOV]), a modified hybrid of SIENA and SIENAX methods (mSIENAX-multi time point for cortical grey matter volume [CGMV]), SIENAX (for baseline lateral ventricle volume [LVV]) and VIENA on 3-dimensional T1-weighted image (for 1-year LVV). Least squares (LS) means and 95% confidence intervals (CIs) are generated for the percent changes from baseline using a mixed-effect model with repeated measures adjusted for baseline volume and age.
A total of 185 patients with a mean (standard deviation [SD]) age of 39.5 (10.7) years were enrolled at data cutoff (02/14/2023) and received ≥1 ozanimod dose; most were White (159; 85.9%), female (145; 78.4%), and DMT-naive (134; 72.4%). Mean (SD) baseline (n=184) brain volume (cm3) and mean (SD) percent change at year 1, respectively, were 1510.4 (130.2) and −0.28% (0.76) for WBV (n=98); 16.2 (1.9) and 0.07% (4.50) for TV (n=97); 619.0 (75.9) and 0.63% (2.13) for CGMV (n=97); 5.9 (0.8) and 0.35% (7.25) for MOV (n=98); and 39.6 (14.7) and 1.16% (7.76) for LVV (n=98). LS mean (95% CI) percent change was −0.28% (−0.43, −0.12) for WBV; 0.07% (−0.82, 0.97) for TV; 0.63% (0.21, 1.06) for CGMV; 0.35% (−0.98, 1.67) for MOV; and 1.14% (−0.38, 2.67) for LVV.
In ENLIGHTEN participants, WBV decreased at a rate consistent with healthy controls. TV, CGMV, and MOV did not decrease significantly, and LVV did not increase significantly, suggesting preservation of these structures.
Authors/Disclosures
Ahmed Z. Obeidat, MD, PhD (Medical College of Wisconsin)
PRESENTER
Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Obeidat has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Genentech. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Obeidat has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi/Genzyme . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon pharmaceuticals . Dr. Obeidat has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sandoz. Dr. Obeidat has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Alexion. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Obeidat has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for EMD Serono. Dr. Obeidat has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Banner life sciences . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Expert opinion and key opinion leader with MJH life sciences . Dr. Obeidat has a non-compensated relationship as a Board member with CMSC that is relevant to AAN interests or activities. Dr. Obeidat has a non-compensated relationship as a Editorial Board Member with IJMSC that is relevant to AAN interests or activities. Dr. Obeidat has a non-compensated relationship as a Reviewer Editor with Frontiers Neurology that is relevant to AAN interests or activities.
Robert Zivadinov, MD, PhD, FAAN (Buffalo Neuroimaging Analysis Center) The institution of Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Filterlex. Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for 3D Communications. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Omnicuris. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurology Live. The institution of Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen.
Robert T. Naismith, MD, FAAN (Washington University) Dr. Naismith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Naismith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol Myers Squib. Dr. Naismith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Naismith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme. Dr. Naismith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Naismith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Naismith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celltrion. Dr. Naismith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Naismith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Naismith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Naismith has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Journal Watch.
Sarah A. Morrow, MD, MSC, FRCPC, FAAN Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIogen Idec. Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono/Merck. Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SanofiGenzyme. Dr. Morrow has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen Idec. Dr. Morrow has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for EMDSerono/Merck. Dr. Morrow has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Dr. Morrow has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Morrow has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for sanofi genzyme. Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS/Celgene. The institution of Dr. Morrow has received research support from EMD Serono. The institution of Dr. Morrow has received research support from Novartis. The institution of Dr. Morrow has received research support from Roche. The institution of Dr. Morrow has received research support from Celgene.
Ann D. Bass, MD (Neurology Center of San Antonio, P.A.) Dr. Bass has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen, EMD Serono, Roche-Genentech, Sanofi-Genzyme, BMS, Horizon Therapeutics, TG Therapeutics, Alexion. Dr. Bass has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, EMD Serono, Roche-Genentech, Sanofi-Genzyme, BMS, Horizon Therapeutics, TG Therapeutics, Alexion. Dr. Bass has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen, EMD Serono, Roche-Genentech, Sanofi-Genzyme, BMS, Horizon Therapeutics, TG Therapeutics, Alexion. The institution of Dr. Bass has received research support from Biogen, EMD Serono, Roche-Genentech, Sanofi-Genzyme, BMS, TG Therapeutics, Alexion.
Emily S. Riser, MD (Alabama Neurology Associates) Dr. Riser has nothing to disclose.
Sibyl E. Wray, MD (Hope Neurology) Dr. Wray has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Wray has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Wray has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb/Celgene. Dr. Wray has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Wray has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wray has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Wray has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi/Genzyme. Dr. Wray has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Wray has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Wray has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for EMD Serono. Dr. Wray has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Roche/Genentech. Dr. Wray has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi/Genzyme. The institution of Dr. Wray has received research support from Biogen. The institution of Dr. Wray has received research support from Atara Biotherapeutics. The institution of Dr. Wray has received research support from Bristol Myers Squibb/Celgene. The institution of Dr. Wray has received research support from Novartis. The institution of Dr. Wray has received research support from Roche/Genentech. The institution of Dr. Wray has received research support from Sanofi/Genzyme. The institution of Dr. Wray has received research support from TG Therapeutics. The institution of Dr. Wray has received research support from EMD Serono. The institution of Dr. Wray has received research support from Pharmaceuticals Corp..
Jon V. Riolo, PhD Dr. Riolo has received personal compensation for serving as an employee of Bristol Myers Squib.
Burhan Z. Chaudhry, MD Dr. Chaudhry has received personal compensation for serving as an employee of Bristol Myers Squibb.
Andrew Thorpe No disclosure on file
Chun-Yen Cheng No disclosure on file
John DeLuca, PhD, ABPP (Kessler Foundation) Dr. DeLuca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. DeLuca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. DeLuca has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Celgene. Dr. DeLuca has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. DeLuca has received research support from Biogen.